Cargando…

In silico Analysis of Publicly Available Transcriptomics Data Identifies Putative Prognostic and Therapeutic Molecular Targets for Papillary Thyroid Carcinoma

BACKGROUND: Thyroid cancer is the most common endocrine malignancy. However, the molecular mechanism involved in its pathogenesis is not well characterized. PURPOSE: The objective of this study is to identify key cellular pathways and differentially expressed genes along the thyroid cancer pathogene...

Descripción completa

Detalles Bibliográficos
Autores principales: Almansoori, Asma, Bhamidimarri, Poorna Manasa, Bendardaf, Riyad, Hamoudi, Rifat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939872/
https://www.ncbi.nlm.nih.gov/pubmed/35330879
http://dx.doi.org/10.2147/IJGM.S345336
_version_ 1784672816046538752
author Almansoori, Asma
Bhamidimarri, Poorna Manasa
Bendardaf, Riyad
Hamoudi, Rifat
author_facet Almansoori, Asma
Bhamidimarri, Poorna Manasa
Bendardaf, Riyad
Hamoudi, Rifat
author_sort Almansoori, Asma
collection PubMed
description BACKGROUND: Thyroid cancer is the most common endocrine malignancy. However, the molecular mechanism involved in its pathogenesis is not well characterized. PURPOSE: The objective of this study is to identify key cellular pathways and differentially expressed genes along the thyroid cancer pathogenesis sequence as well as to identify potential prognostic and therapeutic targets. METHODS: Publicly available transcriptomics data comprising a total of 95 samples consisting of 41 normal, 28 non-aggressive and 26 metastatic papillary thyroid carcinoma (PTC) cases were used. Transcriptomics data were normalized and filtered identifying 9394 differentially expressed genes. The genes identified were subjected to pathway analysis using absGSEA identifying PTC related pathways. Three of the genes identified were validated on 508 thyroid cancer biopsies using RNAseq and TNMplot. RESULTS: Pathway analysis revealed a total of 2193 differential pathways among non-aggressive samples and 1969 among metastatic samples compared to normal tissue. Pathways for non-aggressive PTC include calcium and potassium ion transport, hormone signaling, protein tyrosine phosphatase activity and protein tyrosine kinase activity. Metastatic pathways include growth, apoptosis, activation of MAPK and regulation of serine threonine kinase activity. Genes for non-aggressive are KCNQ1, CACNA1D, KCNN4, BCL2, and PTK2B and metastatic PTC are EGFR, PTK2B, KCNN4 and BCL2. Three of the genes identified were validated using clinical biopsies showing significant overexpression in aggressive compared to non-aggressive PTC; EGFR (p < 0.05), KCNN4 (p < 0.001) and PTK2B (p < 0.001). DrugBank database search identified several FDA approved drug targets including anti-EGFR Vandetanib used to treat thyroid cancer in addition to others that may prove useful in treating PTC. CONCLUSION: Transcriptomics analysis identified putative prognostic targets including EGFR, PTK2B, BCL2, KCNQ1, KCNN4 and CACNA1D. EGFR, PTK2B and KCN44 were validated using thyroid cancer clinical biopsies. The drug search identified FDA approved drugs including Vandetanib in addition to others that may prove useful in treating the disease.
format Online
Article
Text
id pubmed-8939872
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-89398722022-03-23 In silico Analysis of Publicly Available Transcriptomics Data Identifies Putative Prognostic and Therapeutic Molecular Targets for Papillary Thyroid Carcinoma Almansoori, Asma Bhamidimarri, Poorna Manasa Bendardaf, Riyad Hamoudi, Rifat Int J Gen Med Original Research BACKGROUND: Thyroid cancer is the most common endocrine malignancy. However, the molecular mechanism involved in its pathogenesis is not well characterized. PURPOSE: The objective of this study is to identify key cellular pathways and differentially expressed genes along the thyroid cancer pathogenesis sequence as well as to identify potential prognostic and therapeutic targets. METHODS: Publicly available transcriptomics data comprising a total of 95 samples consisting of 41 normal, 28 non-aggressive and 26 metastatic papillary thyroid carcinoma (PTC) cases were used. Transcriptomics data were normalized and filtered identifying 9394 differentially expressed genes. The genes identified were subjected to pathway analysis using absGSEA identifying PTC related pathways. Three of the genes identified were validated on 508 thyroid cancer biopsies using RNAseq and TNMplot. RESULTS: Pathway analysis revealed a total of 2193 differential pathways among non-aggressive samples and 1969 among metastatic samples compared to normal tissue. Pathways for non-aggressive PTC include calcium and potassium ion transport, hormone signaling, protein tyrosine phosphatase activity and protein tyrosine kinase activity. Metastatic pathways include growth, apoptosis, activation of MAPK and regulation of serine threonine kinase activity. Genes for non-aggressive are KCNQ1, CACNA1D, KCNN4, BCL2, and PTK2B and metastatic PTC are EGFR, PTK2B, KCNN4 and BCL2. Three of the genes identified were validated using clinical biopsies showing significant overexpression in aggressive compared to non-aggressive PTC; EGFR (p < 0.05), KCNN4 (p < 0.001) and PTK2B (p < 0.001). DrugBank database search identified several FDA approved drug targets including anti-EGFR Vandetanib used to treat thyroid cancer in addition to others that may prove useful in treating PTC. CONCLUSION: Transcriptomics analysis identified putative prognostic targets including EGFR, PTK2B, BCL2, KCNQ1, KCNN4 and CACNA1D. EGFR, PTK2B and KCN44 were validated using thyroid cancer clinical biopsies. The drug search identified FDA approved drugs including Vandetanib in addition to others that may prove useful in treating the disease. Dove 2022-03-18 /pmc/articles/PMC8939872/ /pubmed/35330879 http://dx.doi.org/10.2147/IJGM.S345336 Text en © 2022 Almansoori et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Almansoori, Asma
Bhamidimarri, Poorna Manasa
Bendardaf, Riyad
Hamoudi, Rifat
In silico Analysis of Publicly Available Transcriptomics Data Identifies Putative Prognostic and Therapeutic Molecular Targets for Papillary Thyroid Carcinoma
title In silico Analysis of Publicly Available Transcriptomics Data Identifies Putative Prognostic and Therapeutic Molecular Targets for Papillary Thyroid Carcinoma
title_full In silico Analysis of Publicly Available Transcriptomics Data Identifies Putative Prognostic and Therapeutic Molecular Targets for Papillary Thyroid Carcinoma
title_fullStr In silico Analysis of Publicly Available Transcriptomics Data Identifies Putative Prognostic and Therapeutic Molecular Targets for Papillary Thyroid Carcinoma
title_full_unstemmed In silico Analysis of Publicly Available Transcriptomics Data Identifies Putative Prognostic and Therapeutic Molecular Targets for Papillary Thyroid Carcinoma
title_short In silico Analysis of Publicly Available Transcriptomics Data Identifies Putative Prognostic and Therapeutic Molecular Targets for Papillary Thyroid Carcinoma
title_sort in silico analysis of publicly available transcriptomics data identifies putative prognostic and therapeutic molecular targets for papillary thyroid carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939872/
https://www.ncbi.nlm.nih.gov/pubmed/35330879
http://dx.doi.org/10.2147/IJGM.S345336
work_keys_str_mv AT almansooriasma insilicoanalysisofpubliclyavailabletranscriptomicsdataidentifiesputativeprognosticandtherapeuticmoleculartargetsforpapillarythyroidcarcinoma
AT bhamidimarripoornamanasa insilicoanalysisofpubliclyavailabletranscriptomicsdataidentifiesputativeprognosticandtherapeuticmoleculartargetsforpapillarythyroidcarcinoma
AT bendardafriyad insilicoanalysisofpubliclyavailabletranscriptomicsdataidentifiesputativeprognosticandtherapeuticmoleculartargetsforpapillarythyroidcarcinoma
AT hamoudirifat insilicoanalysisofpubliclyavailabletranscriptomicsdataidentifiesputativeprognosticandtherapeuticmoleculartargetsforpapillarythyroidcarcinoma